InsidersTradesSigma
Mind Medicine (MindMed) Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Mind Medicine (MindMed) Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Mind Medicine (MindMed) Inc. has published 101 public disclosures. The latest transaction was reported on 26 March 2025 (Cession). Among the most active insiders: Barrow Robert. The full history is free.
101
Insider Decl.
0
Thresholds
€41,471
4 ops.
Buy Volume
€2m
51 ops.
Sell Volume
45Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 26 March 2025
Declarations101 total
6,836 shares@ US$6.74100.0% of flowCommon SharesSEC:0000950170-25-045396:0
2,347 shares@ US$6.7433.6% of flowCommon SharesSEC:0000950170-25-045393:0
6,576 shares@ US$6.7418.9% of flowCommon SharesSEC:0000950170-25-045394:0
21,208 shares@ US$6.749.8% of flowCommon SharesSEC:0000950170-25-045397:0
350,000 shares0Common SharesSEC:0000950170-25-038801:0
150,000 shares0Common SharesSEC:0000950170-25-038798:0
115,000 shares0Common SharesSEC:0000950170-25-038800:0
50,000 shares0Common SharesSEC:0000950170-25-038796:0
6,643 shares@ US$7.4310.5% of flowCommon SharesSEC:0001104659-24-132164:0
19,106 shares@ US$7.4310.1% of flowCommon SharesSEC:0001104659-24-132167:0
4,519 shares@ US$7.4314.8% of flowCommon SharesSEC:0001104659-24-132160:0
2,273 shares@ US$7.4337.3% of flowCommon SharesSEC:0001104659-24-132166:0
2,500 shares@ US$7.1747.5% of flowCommon SharesSEC:0000950170-24-133724:0
Ideal exit: 1 Sept 2025 (T+270)
4,430 shares@ US$5.9810.9% of flowCommon SharesSEC:0000950170-24-109447:0
19,771 shares@ US$5.987.8% of flowCommon SharesSEC:0000950170-24-109449:0
6,871 shares@ US$5.988.1% of flowCommon SharesSEC:0000950170-24-109448:0
2,352 shares@ US$5.9829.0% of flowCommon SharesSEC:0000950170-24-109450:0
3,500 shares@ US$5.9852.5% of flowCommon SharesSEC:0000950170-24-100668:0
Ideal exit: 20 May 2025 (T+270)
50,000 shares@ US$3.70100.0% of flowCommon SharesSEC:0000950170-24-099872:0
500 shares@ US$6.310.2% of flowCommon SharesSEC:0000950170-24-099351:0
Ideal exit: 16 May 2025 (T+270)
500 shares@ US$6.120.2% of flowCommon SharesSEC:0000950170-24-099351:1
Ideal exit: 17 May 2025 (T+270)
17,854 shares@ US$7.2255.3% of flowCommon SharesSEC:0000950170-24-077497:0
6,925 shares@ US$7.2210.3% of flowCommon SharesSEC:0000950170-24-077496:0
15,659 shares@ US$7.227.8% of flowCommon SharesSEC:0000950170-24-077495:0
6,578 shares@ US$9.5012.8% of flowCommon SharesSEC:0000950170-24-036573:0
25 of 101 declarations
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. is a late-stage biopharmaceutical company listed in the United States on the NASDAQ under the ticker MNMD. Headquartered in New York, United States, the company focuses on brain health disorders and has built its identity around rigorous clinical development in psychiatry. MindMed originated as a pioneering psychedelic-medicine biotech, but its current positioning is broader and more disciplined: it now presents itself as an evidence-based neuroscience company developing novel product candidates that target neurotransmitter pathways relevant to mental health. ([ir.mindmed.co](https://ir.mindmed.co/?utm_source=openai)) From an investment perspective, MindMed’s history reflects a transition from early-stage experimentation toward a more advanced clinical platform. The company states that it is developing a pipeline of innovative product candidates, with and without acute perceptual effects, aimed at brain health disorders. Its lead programs include MM120 ODT, which is being developed for major depressive disorder, and MM402, a proprietary form of R(-)-MDMA being studied in autism spectrum disorder. This multi-asset strategy is important because it gives the company several potential value-inflection points rather than reliance on a single program. ([mindmed.co](https://mindmed.co/?utm_source=openai)) MindMed operates in a highly competitive but still emerging sector where differentiation depends on clinical data quality, regulatory execution, and the ability to translate novel science into approvable medicines. It is best viewed as a clinical-stage developer rather than a commercial-stage pharmaceutical company, which means it has no marketed products and remains dependent on successful trial outcomes, future financing decisions, and FDA engagement. In that sense, its market position is defined less by current revenue generation and more by its optionality in a potentially large psychiatric treatment market if its programs continue to de-risk. ([ir.mindmed.co](https://ir.mindmed.co/news-events/press-releases/detail/206/mindmed-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference?utm_source=openai)) Recent corporate and clinical developments have kept the stock in focus. Throughout 2025 and into early 2026, MindMed reported continued advancement of its pipeline, including planned and ongoing late-stage work for MM120 ODT in major depressive disorder and an anticipated Phase 2a study for MM402 in autism spectrum disorder. The company also strengthened its executive team in 2025 with the appointment of Brandi Roberts as Chief Financial Officer, underscoring an emphasis on operational readiness and capital-market discipline. For investors, MNMD on NASDAQ remains a catalyst-driven story in the United States, with future performance tied closely to trial milestones, regulatory updates, and execution across its neuroscience portfolio. ([ir.mindmed.co](https://ir.mindmed.co/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates?utm_source=openai))
